Company Profile

Invitae Corporation is a medical genetics company. The Company is engaged in delivering genetic testing services, digital health solutions, and health data services that support a lifetime of patient care and improved outcomes. It offers genetic testing across multiple clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases and pharmacogenomics. It applies proprietary design, process automation, robotics and bioinformatics software solutions to expand the use and impact of genetic information in sample processing and complex variant interpretation, allowing medical interpretation at scale. The Company also utilizes digital health solutions to improve ease-of-use and to deliver actionable information about risk, prevention, treatment, and monitoring. The Company has served over 3.6 million patients, and over 2.2 million of those patients have made their information available for data sharing.

Employees

1,700

Sector

Biotechnology & Medical Research

More about the company

08/08/24	Invitae Corporation Announces Cessation of Kenneth D. Knight as Chief Executive Officer	CI
08/08/24	Invitae Corporation Announces Cessation of Ana J. Schrank as Chief Financial Officer	CI
08/08/24	Invitae Corporation Announces Board and Executive Cessation	CI
07/08/24	Invitae Corporation Went Out of Business	CI
05/08/24	Labcorp Closes Buyout of Certain Invitae Assets	MT
04/08/24	Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).	CI
02/08/24	Third Amended Joint Liquidation Plan Approved for Invitae Corporation	CI
01/08/24	Labcorp beats Q2 profit and revenue estimates on demand for health tests	RE
01/08/24	Third Amended Joint Liquidation Plan Filed by Invitae Corporation	CI
26/07/24	The trades that could bring down short-seller Andrew Left	RE
22/07/24	Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients	CI
20/07/24	Second Amended Liquidation Plan Approved for Invitae Corporation	CI
19/07/24	Second Amended Joint Liquidation Plan Filed by Invitae Corporation	CI

20/10/23	Goldman Sachs Adjusts Price Target on Invitae to $0.50 From $1, Maintains Sell Rating	MT
15/08/23	Piper Sandler Trims Invitae Price Target to $0.50 From $1.50, Maintains Underweight Rating	MT
21/07/23	Goldman Sachs Adjusts Price Target on Invitae to $1 From $1.50, Maintains Sell Rating	MT
15/05/23	Piper Sandler Cuts Invitae's Price Target to $1.50 From $1.75, Maintains Underweight Rating	MT
15/05/23	Raymond James Downgrades Invitae to Underperform From Market Perform	MT

02-23	Natera Wins Court Battle Over Patented Cancer Testing Technology	AQ
30/10/24	DELFI Diagnostics Names Robert Guigley as Chief Commercial Officer to Expand Access to Early Cancer Screening	AQ
08/08/24	Invitae : Bankruptcy Form 8 K	PU
01/07/24	Invitae : Regulation FD Presentation Form 8 K	PU
07/03/24	Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results	AQ

14/02/24	En Direct des Marchés : Capgemini, Alstom, Airbnb, Ahold, Sony, Nvidia, Walmart, Vicat...
14/02/24	EN DIRECTO DESDE LOS MERCADOS: Arcelormittal, BBVA, Santander, Mapfre, Iberdrola, Neinor Homes, ABN Sony, Heineken...
14/02/24	Bolsa de Madrid: ¿Está cambiando el mercado de valores?
14/02/24	Est-ce que la donne boursière est en train de changer ?
06/02/24	EN DIRECTO DESDE LOS MERCADOS: Grifols, Unicaja Banco, Nintendo, DocuSign, UBS, Infineon, Palantir, MorphoSys, L'Occitane...

Manager	Title	Age	Since
Andrew Spirito CEO	Chief Executive Officer	-	-
Hoki Luk IRC	Investor Relations Contact	-	-
Robert Guigley PRN	Corporate Officer/Principal	-	04/09/2023

Invitae Corporation Share Price

Stocks

NVTA.Q

US46185L1035

Biotechnology & Medical Research

Latest news : Invitae Corporation

Analysts' recommendations: Invitae Corporation

Press Releases: Invitae Corporation

News in other languages: Invitae Corporation

Quotes and Performance

Managers and Directors: Invitae Corporation

Latest insider transactions

Bio Diagnostics & Testing

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/12/23	Thomas Brida	Tax	Compliance Officer	17,404	0.0061%
20/12/23	Robert Nussbaum	Tax	Chief Technology Officer	17,404	0.0061%
13/11/23	David Sholehvar	Free	Chief Operating Officer	850,000	0.3183%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVITAE CORPORATION	-25.00%	-25.00%	-	-	85.95K
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.79%	+11.77%	+112.59%	+302.34%	3.98B
VERACYTE, INC.	-1.98%	+3.50%	+65.84%	+82.47%	3.8B
IOVANCE BIOTHERAPEUTICS, INC.	+3.08%	+51.22%	+231.22%	-9.25%	2.87B
CAREDX, INC.	+2.29%	-0.36%	+305.10%	+392.56%	2.42B
BGI GENOMICS CO., LTD.	+1.83%	+6.63%	-22.02%	-32.77%	2.27B
FREENOME, INC.	+6.37%	0.00%	+5.49%	-	1.26B
SEEGENE, INC.	+6.40%	+14.31%	+2.33%	+35.46%	934M
MARAVAI LIFESCIENCES HOLDINGS, INC.	-0.40%	-4.28%	+198.30%	-40.34%	928M
HANGZHOU ALLTEST BIOTECH CO., LTD.	+1.75%	+5.73%	-36.35%	-5.58%	532M
Average	-0.26%	+10.02%	+95.83%	+90.61%	2.11B
Weighted average by Cap.	+2.17%	+12.86%	+117.06%	+132.88%